News
AGIO
22.73
-2.28%
-0.53
Insider Sell: Agios Pharmaceuticals
Insider Sell: Agios Pharmaceuticals
MT Newswires · 5d ago
TipRanks ‘Perfect 10’ List: These 2 Healthcare Stocks Look Compelling at Current Levels
NASDAQ · 03/05 10:20
TipRanks ‘Perfect 10’ List: These 2 Stock Healthcare Stocks Look Compelling at Current Levels
TipRanks · 03/05 10:20
Relative Strength Alert For Agios Pharmaceuticals
NASDAQ · 03/01 16:53
Agios Pharmaceuticals (AGIO) Moves to Strong Buy: Rationale Behind the Upgrade
NASDAQ · 02/24 17:00
Agios (AGIO) Q4 Earnings Beat Estimates, Revenues Miss
NASDAQ · 02/24 16:49
Oppenheimer Sticks to Their Hold Rating for Agios Pharma (AGIO)
TipRanks · 02/24 16:15
Agios Pharmaceuticals's Return On Capital Employed Insights
Benzinga · 02/24 14:50
Bank of America Securities Remains a Buy on Agios Pharma (AGIO)
TipRanks · 02/24 10:45
Agios Pharmaceuticals (AGIO) Beats Q4 Earnings Estimates
NASDAQ · 02/23 13:45
Perion Network and West Fraser Timber have been highlighted as Zacks Bull and Bear of the Day
NASDAQ · 02/23 13:38
Agios Pharmaceuticals FY EPS $(4.23) Beats $(6.56) Estimate, Sales $14.24M Beat $14.18M Estimate
Benzinga · 02/23 12:20
Agios Pharmaceuticals Swings to Q4 Net Income
Agios Pharmaceuticals Swings to Q4 Net Income
MT Newswires · 02/23 09:29
Notable earnings before Thursday's open
Seeking Alpha · 02/22 15:41
Drug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & More
NASDAQ · 02/22 13:46
Agios Pharma: Multiple Growth Catalysts If Pyrukynd Conversions Pull Through
Seeking Alpha · 02/22 12:10
Piper Sandler Initiates Coverage On Agios Pharmaceuticals with Overweight Rating, Announces Price Target of $41
Benzinga · 02/03 10:02
--Piper Sandler Starts Agios Pharmaceuticals at Overweight With $41 Price Target
--Piper Sandler Starts Agios Pharmaceuticals at Overweight With $41 Price Target
MT Newswires · 02/03 07:38
More
Webull provides a variety of real-time AGIO stock news. You can receive the latest news about Agios Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (LR MDS), and hemolytic anemias.